BACKGROUND Colorectal cancer ranks third and second among common and fatal cancers.The treatment of metastatic colorectal cancer(mCRC)is generally based on XELOX in clinical practice,which includes capecitabine(CAP)an...BACKGROUND Colorectal cancer ranks third and second among common and fatal cancers.The treatment of metastatic colorectal cancer(mCRC)is generally based on XELOX in clinical practice,which includes capecitabine(CAP)and oxaliplatin.Serum tumor markers carcinoembryonic antigen(CEA),carbohydrate antigen(CA)125 and CA199 are prognostic factors for various tumors.AIM To investigate evaluating combined bevacizumab(BEV)and XELOX in advanced colorectal cancer:Serum markers CEA,CA125,CA199 analysis.METHODS In this retrospective study,a total of 94 elderly patients diagnosed with mCRC were recruited and subsequently categorized into two groups based on the distinct treatment modalities they received.The control group was treated with XELOX plus CAP(n=47),while the observation group was treated with XELOX plus CAP and BEV(n=47).Several indexes were assessed in both groups,including disease control rate(DCR),incidence of adverse effects,serum marker levels(CEA,CA125,and CA19)and progression-free survival(PFS).RESULTS After 9 wk of treatment,the serum levels of CEA,CA199 and CA125 in the observation group were significantly lower than those in the control group(P<0.05).Moreover,the PFS of the observation group(9.12±0.90 mo)was significantly longer than that of the control group(6.49±0.64 mo).Meanwhile,there was no statistically significant difference in the incidence of adverse reactions and DCR between the two groups during maintenance therapy(P>0.05).CONCLUSION On the basis of XELOX treatment,the combination of BEV and CAP can reduce serum tumor marker levels and prolong PFS in patients with mCRC.展开更多
目的探讨复方苦参注射液联合卡培他滨^(+)奥沙利铂(capecitabine plus oxaliplatin,XELOX)化疗对结直肠癌术后患者的临床疗效。方法选取2020年1月至2021年12月天津中医药大学第二附属医院普通外科手术后结直肠癌患者70例,根据随机数字...目的探讨复方苦参注射液联合卡培他滨^(+)奥沙利铂(capecitabine plus oxaliplatin,XELOX)化疗对结直肠癌术后患者的临床疗效。方法选取2020年1月至2021年12月天津中医药大学第二附属医院普通外科手术后结直肠癌患者70例,根据随机数字表法分为对照组和干预组,每组35例。对照组仅采用XELOX化疗;干预组在对照组基础上加用复方苦参注射液(规格5 ml/支,国药准字Z14021231)20 ml^(+)250 ml生理盐水静脉滴注,每天1次,连用14 d,停用7 d。两组均以3周为1个疗程,连续6个疗程。比较两组治疗前后外周血T淋巴细胞亚群、CEA水平及不良反应发生率。结果治疗后,干预组CD3^(+)、CD3^(+)CD4^(+)和CD4^(+)/CD8^(+)水平且显著高于对照组[(78.74±6.16)比(67.94±5.35),(51.33±9.39)比(37.89±4.91),(2.84±1.35)比(1.24±0.30)],差异均有统计学意义(P<0.05)。治疗后,干预组血清CEA水平显著低于对照组[(29.30±14.90)ng/ml比(58.01±19.07)ng/ml],差异有统计学意义(P<0.05)。治疗后,干预组骨髓抑制、胃肠道反应、肝肾功能异常的发生率均低于对照组(17.1%比42.9%,31.4%比57.1%,14.3%比37.1%),差异均有统计学意义(P<0.05)。结论复方苦参注射液联合XELOX化疗对结直肠癌术后患者免疫力具有较好疗效,且降低了化疗引起的不良反应发生率。展开更多
文摘BACKGROUND Colorectal cancer ranks third and second among common and fatal cancers.The treatment of metastatic colorectal cancer(mCRC)is generally based on XELOX in clinical practice,which includes capecitabine(CAP)and oxaliplatin.Serum tumor markers carcinoembryonic antigen(CEA),carbohydrate antigen(CA)125 and CA199 are prognostic factors for various tumors.AIM To investigate evaluating combined bevacizumab(BEV)and XELOX in advanced colorectal cancer:Serum markers CEA,CA125,CA199 analysis.METHODS In this retrospective study,a total of 94 elderly patients diagnosed with mCRC were recruited and subsequently categorized into two groups based on the distinct treatment modalities they received.The control group was treated with XELOX plus CAP(n=47),while the observation group was treated with XELOX plus CAP and BEV(n=47).Several indexes were assessed in both groups,including disease control rate(DCR),incidence of adverse effects,serum marker levels(CEA,CA125,and CA19)and progression-free survival(PFS).RESULTS After 9 wk of treatment,the serum levels of CEA,CA199 and CA125 in the observation group were significantly lower than those in the control group(P<0.05).Moreover,the PFS of the observation group(9.12±0.90 mo)was significantly longer than that of the control group(6.49±0.64 mo).Meanwhile,there was no statistically significant difference in the incidence of adverse reactions and DCR between the two groups during maintenance therapy(P>0.05).CONCLUSION On the basis of XELOX treatment,the combination of BEV and CAP can reduce serum tumor marker levels and prolong PFS in patients with mCRC.